FDA clears Thoratec's Vectra Access Graft:
This article was originally published in Clinica
Thoratec Laboratories has received 510(k) marketing clearance from the US FDA for its Vectra Vascular Access Graft. The device incorporates the Pleasanton, California-based company's biomaterial, Thoralon, and is designed to provide access to the bloodstream in end-stage renal disease patients undergoing haemodialysis. It has been available in Japan, Australia and Canada for several years, and in Europe since last year.